- Home
- ARVN vs BFS Comparison
ARVN vs BFS Comparison
Compare ARVN & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- BFS
- Stock Information
- Founded
- ARVN 2015
- BFS 1993
- Country
- ARVN United States
- BFS United States
- Employees
- ARVN N/A
- BFS N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- BFS Real Estate Investment Trusts
- Sector
- ARVN Health Care
- BFS Real Estate
- Exchange
- ARVN Nasdaq
- BFS Nasdaq
- Market Cap
- ARVN 676.2M
- BFS 770.5M
- IPO Year
- ARVN 2018
- BFS 1993
- Fundamental
- Price
- ARVN $10.59
- BFS $30.09
- Analyst Decision
- ARVN Buy
- BFS
- Analyst Count
- ARVN 23
- BFS 0
- Target Price
- ARVN $17.80
- BFS N/A
- AVG Volume (30 Days)
- ARVN 2.3M
- BFS 71.7K
- Earning Date
- ARVN 11-05-2025
- BFS 11-06-2025
- Dividend Yield
- ARVN N/A
- BFS 7.80%
- EPS Growth
- ARVN N/A
- BFS N/A
- EPS
- ARVN N/A
- BFS 1.14
- Revenue
- ARVN $312,300,000.00
- BFS $282,618,000.00
- Revenue This Year
- ARVN N/A
- BFS $6.92
- Revenue Next Year
- ARVN N/A
- BFS $4.90
- P/E Ratio
- ARVN N/A
- BFS $26.51
- Revenue Growth
- ARVN 93.86
- BFS 5.61
- 52 Week Low
- ARVN $5.90
- BFS $29.16
- 52 Week High
- ARVN $27.00
- BFS $41.51
- Technical
- Relative Strength Index (RSI)
- ARVN 59.44
- BFS 48.16
- Support Level
- ARVN $9.27
- BFS $29.60
- Resistance Level
- ARVN $11.51
- BFS $30.47
- Average True Range (ATR)
- ARVN 0.53
- BFS 0.65
- MACD
- ARVN 0.02
- BFS 0.07
- Stochastic Oscillator
- ARVN 59.15
- BFS 66.04
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About BFS Saul Centers Inc.
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.